Top

Published in:

01-12-2005 | Original Article

Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England

Authors: Beate Aurich Barrera, Lynda Wilton, Scott Harris, Saad A. W. Shakir

Published in: Osteoporosis International | Issue 12/2005

Abstract

Risedronate sodium is indicated in postmenopausal women for the prevention and treatment of osteoporosis and for the treatment of Paget’s disease. Our aim was to evaluate the safety of risedronate in a large cohort of patients prescribed risedronate by general practitioners (GPs) in England, soon after it was marketed. An observational cohort study was conducted using the technique of prescription-event monitoring (PEM). Exposure data were obtained from dispensed National Health Service prescriptions issued between September 2000 and June 2002. Outcome data were collected by sending questionnaires to prescribing GPs requesting them to report any events that had occurred since starting risedronate, demographic details, indication, start and stop dates, reasons for stopping, suspected adverse drug reactions (ADRs) and causes of death. Event rates calculated as incidence densities (IDs) separately, for Paget’s disease group and all other patients (osteoporosis group) were ranked and the difference between IDs in month 1 and months 2–6 calculated. The osteoporosis cohort comprised 13,180 patients (10,934 [83.0%] female); median ages for female and male patients were 73 and 69 years, respectively. The most frequently reported event in the first month of treatment was dyspepsia, being also amongst the most frequently reported reasons for stopping risedronate and suspected ADR. Adverse events assessed as possibly or probably related to risedronate included, six of facial edema and one each of Stevens-Johnson syndrome, swollen tongue, palpitation and episcleritis. Risedronate was fairly well tolerated. Adverse events affecting skin, eye, cardiovascular and immunological systems were identified. Prescribing doctors should be aware of these and monitor their patients accordingly.

Summary of product characteristics (2000) Actonel 5 mg. Procter and Gamble Pharmaceuticals UK, pp 1–8

Summary of product characteristics (2000), Actonel 30 mg. Procter and Gamble Pharmaceuticals UK, 1–6

Summary of product characteristics (2003), Actonel once a week 35 mg. Procter and Gamble Pharmaceuticals UK

Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5(1):65–74PubMed

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340PubMed

Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85(5):1895–1900CrossRefPubMed

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91PubMed

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352CrossRefPubMed

Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr (1998) Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83(2):396–402CrossRefPubMed

10.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7(5):488–495

11.

Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23(4):517–523CrossRefPubMed

12.

Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study Group. Am J Med 106(5):513–520CrossRefPubMed

13.

Brown JP, Hosking DJ, Ste-Marie L, Johnston CC Jr, Reginster J, Ryan WG, Johnson TD, Bekker PJ (1999) Risedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response study. Calcif Tissue Int 64(2):93–99CrossRefPubMed

14.

Brown JP, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW (2000) Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 26(3):263–267CrossRefPubMed

15.

The Royal College of Physicians, The Bone and Tooth Society of Great Britain, The National Osteoporosis Society (2002) Management of glucocorticoid-induced osteoporosis—Guidelines for prevention and treatment. Royal College of Physicians of London, London, pp 1–57

16.

Anonymous (2001) Drugs affecting bone metabolism. In: Mehta DK (ed) British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, pp 359–362

17.

Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within 1 year in men on corticosteroid therapy. Calcif Tissue Int 69(4):242–247CrossRefPubMed

18.

Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67(4):277–285CrossRefPubMed

19.

Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant D, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11(4):331–337

20.

Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15(6):1006–1013PubMed

21.

Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42(11):2309–2318CrossRefPubMed

22.

Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949–2954PubMed

23.

Reid IR (2003) Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 15(4):458–463CrossRefPubMed

24.

Drake WM, Kendler DL, Brown JP (2001) Consensus statement on the modern therapy of Paget’s disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9–10, 2000. Clin Ther 23(4):620–626CrossRefPubMed

25.

Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA (2002) 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 29(9):1965–1974PubMed

26.

Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Roberts A, Zippel H, Adami S, Ernst TF, Stevens KP (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77(3):262–270PubMed

27.

Lanza FL, Rack MF, Li Z, Krajewski SA, Blank MA (2000) Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs aspirin in healthy postmenopausal women. Aliment Pharmacol Ther 14(12):1663–1670CrossRefPubMed

28.

Lanza FL, Schwartz H, Sahba B, Malaty HM, Musliner T, Reyes R, Quan H, Graham DY (2000) An endoscopic comparison of the effects of alendronate and risedronate on upper-gastrointestinal mucosae. Am J Gastroenterol 95(11):3112–3117CrossRefPubMed

29.

Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119(3):631–638PubMed

30.

Vinas G, Olive A, Holgado S, Costa J (2002) Episcleritis secondary to risedronate. Med Clin (Barc) 118(15):598–599

31.

Fraunfelder FW, Fraunfelder FT, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135 (2):219–222CrossRefPubMed

32.

Rey J, Daumen-Legre V, Pham T, Bernard P, Dahan L, Acquaviva P, Lafforgue P (2000) Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review. Joint Bone Spine 67(4):337–340PubMed

33.

O’Donnell N, Rao GP, Aguis-Fernandez A (1995) Paget’s disease: Ocular complications of disodium pamidronate treatment. Br J Clin Pract 49 (5):272–273PubMed

34.

De S, Meyer P, Crisp AJ (1995) Pamidronate and Uveitis. Br J Rheumatol 34(5):479

35.

Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118 (2):220–224PubMed

36.

Salmen S, Berrueta L, Sanchez N, Montes H, Borges L (2002) Nongranulomatous anterior uveitis associated with alendronate therapy. Invest Clin 43(1):49–52PubMed

37.

Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117(6):837–838PubMed

38.

Fraunfelder FW, Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348(12):1187–1188CrossRefPubMed

39.

Springuel P, McMorran M (2003) Bisphosphonates and ocular disorders; Canadian Adverse Drug Reaction Newsletter. Canada, Health Canada. Pamphlet

40.

Shakir SAW (2002) PEM in the UK. In: Mann RD, Andrews EB (eds) Pharmacovigilance. Wiley pp 333–344

41.

Venulet J, Bankowski Z (1998) Harmonizing adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences. Drug Saf 19(3):165–172PubMed

42.

Shakir SA (2004) Causality and correlation in pharmacovigilance. In: Talbot PWJ (ed) Stephens’ detection of new adverse drug reactions. Wiley, Chichester, UK, pp 329–343

43.

CIOMS.WHO (1993) International guidelines for biomedical research involving human subjects. CIOMS WHO, Geneva

44.

Royal College of Physicians of London (1996) Guidelines on practice of ethical committees in medical research involving human subjects. Royal College of Physicians of London, pp 1–8

45.

Multi-Centre Research Ethics Committee (2000) Guidance notes. Examples of enquiries and surveys in the public interest where no reference to a research ethics committee is necessary. Appendix C:21

46.

Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358(9296):1872–1873CrossRefPubMed

47.

McAvoy BR, Kramer EF (1996) General practice postal surveys: a questionnaire too far? BMJ 313(7059):732–733PubMed

48.

Biswas PN, Wilton LV, Shakir SA (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507–514

49.

Lichtenberger LM, Romero JJ, Gibson GW, Blank MA (2000) Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45(9):1792–1801PubMed

50.

Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14(3):259–262

51.

Blank MA, Gibson GW, Myers WR, Dierckman TA, Phipps RJ, Smith PN (2000) Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther 14(9):1215–1223CrossRefPubMed

52.

WHO Collaborating Centre for International Drug Monitoring (2002) Caveat document, accompanying statement to data released from the WHO Collaborating Centre. 1. WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden

53.

Bate A, Lindquist M, Edwards IR, Olsson S, Orre S, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation . Eur J Clin Pharmacol 54:315–321CrossRefPubMed

54.

Summary of product characteristics (2005) Actonel 5 mg. Procter and Gamble Pharmaceuticals UK, pp 1–8

55.

Summary of product characteristics (2005) Actonel 30 mg. Procter and Gamble Pharmaceuticals UK, pp 1–6

56.

Steinbuch M, D’Agostino RB, Mandel JS, Gabrielson E, McClung MR, Stemhagen A, Hofman A (2002) Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 35(3):320–326CrossRefPubMed

Title: Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England
Authors: Beate Aurich Barrera
Lynda Wilton
Scott Harris
Saad A. W. Shakir
Publication date: 01-12-2005
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 12/2005
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-005-1986-1

At a glance: The STEP trials

Springer Medicine

Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2005

Fracture Reduction Affects Medicare Economics (FRAME): Impact of increased osteoporosis diagnosis and treatment

Bone mineral density in men with genetic hemochromatosis and HFE gene mutation

The aluminum content of bone increases with age, but is not higher in hip fracture cases with and without dementia compared to controls

The relationship of vitamin D status to bone mineral density in an Italian population of postmenopausal women

Half of the patients with an acute hip fracture suffer from hypovitaminosis D: a prospective study in southeastern Finland

The relation of the Xbal and Pvull polymorphisms of the estrogen receptor gene and the CAG repeat polymorphism of the androgen receptor gene to peak bone mass and bone turnover rate among young healthy men